Abeona Therapeutics
ABEO
48 hedge funds and large institutions have $128M invested in Abeona Therapeutics in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 19 closing their positions.
1,665% more call options, than puts
Call options by funds: $3.69M | Put options by funds: $209K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
22% more capital invested
Capital invested by funds: $105M → $128M (+$23.1M)
20.78% more ownership
Funds ownership: 52.81% → 73.59% (+21%)
14% less funds holding
Funds holding: 56 → 48 (-8)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$18.8M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$9.4M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$8.93M |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$6.37M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.24M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$935K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$612K |
| 4 |
Man Group
London,
United Kingdom
|
-$535K |
| 5 |
HF
HRT Financial
New York
|
-$500K |
ABEO Hedge Fund Activity: Q2 2024 in Review
48 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2024, worth a combined $128M — up 22% from $105M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ABEO and 12 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 25 added.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $18.8M. The largest seller was Goldman Sachs, exiting entirely with an estimated $1.24M sold.
- 48 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2024, down from 56 in Q1 2024.
- Funds reported $128M of Abeona Therapeutics stock for Q2 2024, up 22% quarter-over-quarter.
- 12 funds opened new Abeona Therapeutics positions in Q2 2024 and 19 closed out, a net change of -7 holders.
- The largest Abeona Therapeutics buyer in Q2 2024 was Suvretta Capital Management, an estimated $18.8M added.
- The largest Abeona Therapeutics seller in Q2 2024 was Goldman Sachs, an estimated $1.24M sold.
Based on aggregated 13F filings for Q2 2024.